M&A Deal Summary

Immedica Pharma Acquires Marinus

On December 30, 2024, Immedica Pharma acquired life science company Marinus for 151M USD

Acquisition Highlights
  • This is Immedica Pharma’s 1st transaction in the Life Science sector.
  • This is Immedica Pharma’s largest (disclosed) transaction.
  • This is Immedica Pharma’s 1st transaction in the United States.
  • This is Immedica Pharma’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2024-12-30
Target Marinus
Sector Life Science
Buyer(s) Immedica Pharma
Deal Type Merger
Deal Value 151M USD

Target

Marinus

Radnor, Pennsylvania, United States
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s product, ZTALMY (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. Marinus is based in Radnor, Pennsylvania.

Search 202,196 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Immedica Pharma

Stockholm, Sweden
Category Company
Sector Life Science
Employees40
Revenue 430M SEK (2019)
DESCRIPTION

Immedica Pharma provides commercialization and distribution of orphan and niche specialty pharmaceuticals across Europe and the Middle East. Immedica Pharma is based in Stockholm, Sweden.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Merger) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal